The FDA approved Merck’s Welireg (belzutifan) plus Keytruda (pembrolizumab) as an adjuvant combination for high-risk clear cell renal cell carcinoma after surgery, according to a Dana-Farber-linked development. The approval moves the regimen into post-operative treatment, positioning the combination as a new standard-seeking strategy at an earlier disease stage. The Merck dual-therapy approach reflects continued emphasis on immune checkpoint plus HIF-2α pathway modulation in RCC, aiming to reduce recurrence risk when residual disease may be minimal. Clinicians will now need to operationalize dosing and patient selection in the adjuvant setting. For biotech and pharma portfolios, the decision reinforces regulatory openness to combination logic across distinct tumor microenvironment drivers, especially in oncology subtypes where adjuvant endpoints are tightly defined.